국가: 아일랜드
언어: 영어
출처: HPRA (Health Products Regulatory Authority)
CLOSANTEL
Elanco Animal Health, Eli Lilly and Company Limited
QP52AG09
CLOSANTEL
5 %w/v
Oral Suspension
LM: Licensed Merchant as defined in relevant national legislation
Sheep
closantel
Endoparasiticide
Authorised
2013-01-18
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Flukiver 5% w/v Oral Suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance Closantel (as Clostanel sodium) 50 mg/ml Excipients: For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Oral suspension. A white suspension 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Sheep and lambs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment and control of adult and immature liver fluke, haematophagous nematodes and larval stages of some arthropods in sheep. Liver fluke: _Fasciola hepatica_ (average efficacy against 6 week immature stages is 86%) _Fasciola gigantica_ Haematophagous nematodes _Haemonchus contortus_ (including benzimidazole resistant strains) _Chabertia ovina_ _Gaigeria pachyscelis_ Arthropods _Oestrus ovis_ (Sheep Nasal Bot Fly) Ticks (_lxodes ricinus_) feeding on sheep at the time of treatment are likely to produce fewer viable eggs. I R I S H M E D I C I N E S B O A R D ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _2_ _7_ _/_ _0_ _3_ _/_ _2_ _0_ _1_ _4_ _C_ _R_ _N_ _ _ _7_ _0_ _1_ _7_ _2_ _7_ _7_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 4.3 CONTRAINDICATIONS Do not use in animals with known hypersensitivity to the active ingredient. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy: • Too frequent and repeated use of anthelmintics from th 전체 문서 읽기